SEARCH

SEARCH BY CITATION

References

  • 1
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539553.
  • 2
    Executive Summar. of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:24862497.
  • 3
    Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:27352752.
  • 4
    Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:10591062.
  • 5
    McFarlane SI, Muniyappa R, Shin JJ, et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004;23:110.
  • 6
    Yamaguchi T, Sugimoto T, Yano S. et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J. 2002;49:211217.
  • 7
    Adami S, Braga V, Zamboni M. et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int. 2004;74:136142.
  • 8
    Cappuccio FP, Meilahn E, Zmuda JM, et al. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999;354:971975.
  • 9
    Bahtiyar G, Farag A, Guber H, et al. Assessment of hypertension as a risk factor for low bone mineral density in elderly men [abstract]. J Clin Densitom. 2005;8:40.
  • 10
    Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens. 2001;14:704707.
  • 11
    Cirillo M, Galletti F, Strazzullo P. et al. On the pathogenetic mechanism of hypercalciuria in genetically hypertensive rats of the Milan strain. Am J Hypertens. 1989;2:741746.
  • 12
    Castro JP, Joseph LA, Shin JJ, et al. Differential effect of obesity on bone mineral density in white, Hispanic and African American women: a cross sectional study. Nutr Metab (Lond). 2005;2:9.
  • 13
    Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001;86:20322042.
  • 14
    Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109142.
  • 15
    Armour KE, Armour KJ, Gallagher ME. et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology. 2001;142:760766.
  • 16
    Wimalawansa SJ. Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res. 2000;15:22402244.
  • 17
    McFarlane SI, Muniyappa R, Francisco R. et al. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87:14511458.
  • 18
    Mundy G, Garrett R, Harris S. et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:19461949.
  • 19
    Fisher JE, Rogers MJ, Halasy JM. et al. Alendronate mechanism of action: geranyl-geraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133138.
  • 20
    Ylitalo R, Oksala O, Yla-Herttuala S, et al. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med. 1994;123:769776.
  • 21
    Van Der Meer IM, Iglesias del Sol A, Hak AE, et al. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. Stroke. 2003;34:23742379.
  • 22
    Van Der Klift M, Pols HA, Hak AE, et al. Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif Tissue Int. 2002;70:443449.
  • 23
    Hirose K, Tomiyama H, Okazaki R. et al. Increased pulse wave velocity associated with reduced calcaneal quantitative osteosono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab. 2003;88:25732578.
  • 24
    Hak AE, Pols HA, Van Hemert AM, et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Tromb Vasc Biol. 2000;20:19261931.
  • 25
    Browner WS, Seeley DG, Vogt TM. et al. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet. 1991;338:355358.
  • 26
    Von Der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999;106:273278.
  • 27
    Parhami F, Basseri B, Hwang J. et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002;91:570576.
  • 28
    Parhami F, Jackson SM, Thintut Y. et al. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res. 1999;14:20672078.
  • 29
    Perez-Castrillon JL, Justo I, Silva J, et al. Bone mass and bone modelling markers in hypertensive postmenopausal women. J Hum Hypertens. 2003;17:107110.
  • 30
    Izawa Y, Sagara K, Kadota T. et al. Bone disorders in spontaneously hypertensive rat. Calcif Tissue Int. 1985;37:605607.
  • 31
    Schwartz AV, Sellmeyer DE, Ensrud KE. et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:3238.
  • 32
    Schwartz AV. Diabetes mellitus: does it affect bone? Calcif Tissue Int. 2003;73:515519.
  • 33
    Van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med. 1995;122:409414.
  • 34
    Miller PD, Siris ES, Barrett-Connor E, et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res. 2002;17:22222230.
  • 35
    Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:28152822.
  • 36
    Albala C, Yanez M, Devoto E. et al. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996;20:10271032.
  • 37
    Ribot C, Tremollieres F, Pouilles JM. et al. Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone. 1987;8:327331.
  • 38
    Ribot C, Tremollieres F, Pouilles JM. The effect of obesity on postmenopausal bone loss and the risk of osteoporosis. Adv Nutr Res. 1994;9:257271.
  • 39
    Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab. 1993;77:683686.
  • 40
    Ravn P, Cizza G, Bjarnason NH. et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res. 1999;14:16221627.
  • 41
    Gasperino J. Ethnic differences in body composition and their relation to health and disease in women. Ethn Health. 1996;1:337347.
  • 42
    Rizzo M, Di Fede G, Mansueto P, et al. Statins and osteoporosis: myth or reality? Minerva Med. 2004;95:521527.
  • 43
    Jackson B, Gee AN, Guyon-Gellin Y, et al. Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i). Arzneimittelforschung. 2000;50:380386.
  • 44
    Koshiyama H, Nakamura Y, Tanaka S. et al. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab. 2000;85:27932796.
  • 45
    Maugeri D, Panebianco P, Rosso D, et al. Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis. Arch Gerontol Geriatr. 2002;34:117122.